Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. reported that, after a director’s resignation in March led to a temporary failure to meet Nasdaq Listing Rule 5605(c)(2)(A) audit committee requirements, its Board has reconstituted the Audit Committee. Effective July 24, 2026, the committee consists of Dr. Deborah Ascheim, Ms. Leah Rush Cann, Dr. George Paletta and Ms. Ursula Ungaro.
The company states that each Audit Committee member qualifies as independent, and that Ms. Cann qualifies as an audit committee financial expert under Item 407(d)(5)(ii) of Regulation S-K and Nasdaq Listing Rule 5605(c)(2), aligning the committee’s composition with applicable listing standards.
Longeveron Inc. reports the initial beneficial ownership position of its Chief Financial Officer, Marie Washburn. She directly holds 101,030 shares of Class A Common Stock, including restricted stock units that are subject to time-based vesting, net of shares already withheld to cover related tax obligations. No new transactions are reported.
Longeveron Inc. director Arjun JJ Desai filed an initial insider ownership report on Form 3. The report lists 0.0000 shares of Class A Common Stock beneficially owned as of July 2, 2026, and a footnote states that no securities are beneficially owned.
Longeveron Inc. updated the employment terms of Chief Executive Officer Stephen Willard through a revised letter agreement dated July 8, 2026. Mr. Willard remains entitled to a base salary of $500,000 per year, now without the prior deferral, and becomes eligible for an annual cash bonus with a 45% target of base salary, 80% tied to corporate goals and 20% at the Board’s discretion, payable by March 31 following each fiscal year.
Upon termination by the company without "Cause" or by Mr. Willard for "Good Reason", he may receive earned but unpaid prior bonuses and a prorated current-year bonus. If such a termination occurs within six (6) months after a "Change in Control" under the company’s incentive plan, he is also eligible for a lump sum equal to twelve (12) months of base salary plus 100% of target bonus, full vesting of outstanding equity awards, an extended one-year option exercise period, and certain health coverage benefits. His initial equity grants of 200,000 restricted stock units and options for 200,000 shares now vest quarterly over three years instead of four.
Longeveron Inc. director Leah Rush Cann has filed an initial beneficial ownership report indicating she holds no shares of the company’s Class A Common Stock. The report shows total beneficial ownership of 0 shares, with a footnote explicitly stating that no securities are beneficially owned.
Longeveron Inc. director Deborah Ascheim filed an initial ownership report indicating that she beneficially owns no securities of the company. The filing covers Class A Common Stock and shows 0.0000 shares beneficially owned as of the reported date.
Longeveron Inc. reported that Chief Scientific Officer and significant shareholder Joshua Hare received equity awards rather than making open-market purchases. He was granted 600,000 Class B common stock shares through time-based vesting RSUs. Following this award, he directly holds 1,321,796 Class B shares, including RSUs subject to future vesting.
He also received stock options on 400,000 Class B shares at an exercise price of $0.65 per share, vesting quarterly over a three-year period beginning on October 1, 2026 and expiring on July 6, 2036. Class B common stock is not registered under the Securities Exchange Act of 1934, has five votes per share, and is convertible into common stock on a one-for-one basis at the holder’s option.
Longeveron Inc. reported that its Executive Chairman received special equity awards under the company’s 2021 Incentive Award Plan. The grants recognize his role in completing a March 2026 financing transaction and provide additional incentives for continued service.
The awards total 600,000 restricted stock units (RSUs) and 400,000 non-qualified stock options, all granted on July 6, 2026. The RSUs and options vest quarterly over three years starting October 1, 2026 and settle in, or become exercisable for, Class B Common Stock, which carries five votes per share and is convertible into Class A Common Stock.
Longeveron Inc. Chief Executive Officer Willard Stephen H reported a tax-related share disposition. On July 1, 2026, 18,046 shares of Class A Common Stock were withheld at an average price of $0.7291 per share to cover tax obligations tied to a restricted stock unit vesting.
This was not an open-market sale but a payment of tax liability by delivering shares. After the withholding, the CEO directly holds 771,681 shares of Longeveron Inc., and the position also includes restricted stock units that remain subject to future vesting.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported a tax-related share disposition. On the vesting of a restricted stock unit (RSU) award, 22,505 shares of Class A Common Stock were withheld at $0.7291 per share to satisfy tax obligations. This was not an open-market sale, but an automatic tax-withholding mechanism. After this RSU-related withholding, Locklear directly held 443,181 shares, which include RSUs that are still subject to future vesting.